Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease

NCT03105102 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03105102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03105102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 9, 2018
Completion date
February 28, 2029
Enrollment
1,336 (actual)
Sites
496

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease